Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  • Christoph Wanner
  • Ulla Feldt-Rasmussen
  • Ana Jovanovic
  • Aleš Linhart
  • Meng Yang
  • Elvira Ponce
  • Eva Brand
  • Dominique P Germain
  • Derralynn A Hughes
  • John L Jefferies
  • Ana Maria Martins
  • Albina Nowak
  • Bojan Vujkovac
  • Frank Weidemann
  • Michael L West
  • Alberto Ortiz
View graph of relations

AIMS: Long-term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long-term cardiomyopathy and kidney function outcomes after agalsidase beta treatment with preceding treatment-naive outcomes.

METHODS AND RESULTS: Self-controlled pretreatment and post-treatment comparison (piecewise mixed linear modelling) included Fabry female patients ≥18 years at treatment initiation who received agalsidase beta (0.9-1.1 mg/kg every other week) for ≥2 years, with ≥2 pretreatment and ≥2 post-treatment outcome measurements during 10-year follow-up. Left ventricular posterior wall thickness (LVPWT)/interventricular septal thickness (IVST) and estimated glomerular filtration rate (eGFR, Chronic Kidney Disease Epidemiology Collaboration creatinine equation) analyses included 42 and 86 patients, respectively, aged 50.0 and 46.3 years at treatment initiation, respectively. LVPWT and IVST increased pretreatment (follow-up 3.5 years) but stabilized during 3.6 years of treatment (LVPWT: n = 38, slope difference [95% confidence interval (CI)] = -0.41 [-0.68, -0.15] mm/year, Ppre-post difference <0.01; IVST: n = 38, slope difference = -0.32 [-0.67, 0.02] mm/year, Ppre-post difference = 0.07). These findings were not modified by renal involvement or antiproteinuric agent use. Compared with the treatment-naive period (follow-up 3.6 years), eGFR decline remained modest and stabilized within normal ranges during 4.1 years of treatment (slope difference, 95% CI: -0.13 [-1.15, 0.89] mL/min/1.73m2 /year, Ppre-post difference = 0.80).

CONCLUSIONS: Cardiac hypertrophy, progressing during pretreatment follow-up, appeared to stabilize during sustained agalsidase beta treatment. eGFR decline remained within normal ranges. This suggests that treatment may prevent further Fabry-related progression of cardiomyopathy in female patients and maintain normal kidney function.

Original languageEnglish
JournalESC Heart Failure
Volume7
Issue number3
Pages (from-to)825-834
Number of pages10
ISSN2055-5822
DOIs
Publication statusPublished - Jun 2020

ID: 59977866